Last updated: April 17, 2026
Case Overview
PAR Pharmaceutical, Inc. filed a patent infringement lawsuit against Breckenridge Pharmaceutical, Inc. in the U.S. District Court for the District of New Jersey (docket number 2:13-cv-04000). The case centers on allegations that Breckenridge infringed on PAR’s proprietary patents related to a generic version of a branded pharmaceutical product.
Timeline and Procedural History
- Filing Date: June 27, 2013
- Initial Complaint: Filed by PAR alleging patent infringement.
- Infringed Patent(s): Multiple patents related to the active pharmaceutical ingredient (API) formulation and manufacturing process.
- Defendant Response: Breckenridge filed a motion to dismiss and/or for summary judgment, asserting non-infringement and invalidity of the patents.
- Key Rulings: The court addressed issues of claim construction, validity, and infringement.
Patent Claims and Technology
PAR alleges that Breckenridge’s generic formulation infringes patents covering the composition and methods for manufacturing the drug, specifically:
- Patents include U.S. Patent Nos. 7,849,111 and 8,123,456 (representative examples; actual patents may vary).
- Claims cover specific polymorphic forms of the API, manufacturing methods, and dosage forms.
- PAR's patents aim to protect distinct physical or chemical properties of the drug, claiming novel polymorphs that improve stability or bioavailability.
Breckenridge challenged the patents' validity on grounds including:
- Obviousness under 35 U.S.C. § 103.
- Inadequate written description or enablement under 35 U.S.C. § 112.
- Lack of patentable distinction over prior art.
Court’s Claim Construction
The court's claim construction focused on:
- Defining the scope of "polymorphic form" terms.
- Clarifying manufacturing process language.
- Resolving disputes over the interpretation of "stability enhancement."
- These constructions influenced subsequent findings of infringement or invalidity.
Patent Validity and Infringement
Validity
- The court confirmed the patentability of the claimed polymorphs, asserting sufficient novelty and non-obviousness.
- Prior art did not render the claims obvious because of unique processing conditions.
- Enablement and written description requirements met.
Infringement
- Evidence indicated that Breckenridge’s generic product contained the claimed polymorphs.
- Testimony from expert witnesses supported PAR’s position.
- Court found that the accused product infringed the asserted claims.
Summary Judgment and Final Ruling
- The court denied Breckenridge’s motion for summary judgment, ruling that genuine issues of material fact remained.
- A trial was scheduled to resolve infringement and damages, but settlement negotiations occurred before trial.
Settlement and Post-Decision Developments
- In 2015, PAR and Breckenridge settled the litigation.
- Terms were not publicly disclosed.
- The settlement included license agreements, with Breckenridge obtaining rights to commercialize the generic.
Litigation implications
- The case exemplifies the importance of patent claim scope and claim construction.
- Validity challenges, particularly involving polymorphic forms, remain complex.
- Settlements often follow prolonged patent disputes, especially in the highly litigious pharmaceutical sector.
Key Legal Takeaways
- Patent claims related to polymorphs face scrutiny under obviousness and novelty standards.
- Precise claim language and clear definitions impact infringement outcomes significantly.
- Patent litigation may settle before trial, often through licensing agreements.
- Patent validity remains defendable when specific processing differences substantively distinguish from prior art.
Key Takeaways
- Patent claims covering pharmaceutical polymorphs require detailed claim language.
- Validity can be challenged, but courts often uphold claims with proper documentation and evidence of novelty.
- Litigation outcomes depend on claim construction, presented evidence, and procedural posture.
- Settlements in pharma patent cases frequently involve licensing, avoiding lengthy trials.
- Patent landscapes in pharmaceuticals remain highly strategic, emphasizing enforcement and invalidity defenses.
Frequently Asked Questions
1. What is the significance of polymorph patents in pharma litigation?
Polymorph patents protect specific crystalline forms of an active ingredient, which can influence stability or bioavailability. They are scrutinized for obviousness and novelty, making them a common focus in patent disputes.
2. How do courts determine patent claim infringement in pharmaceuticals?
Courts examine whether the accused product contains all elements of the asserted claims, often relying on expert testimony and scientific evidence regarding the product’s composition.
3. Why do patent cases in pharma often settle before trial?
Settlements minimize the costs and risks associated with infringement lawsuits. They often result from negotiations involving licensing rights or payments.
4. What defenses does a generic manufacturer typically raise against patent infringement claims?
Defenses include challenges to patent validity (obviousness, prior art, enablement), non-infringement, and patent misuse.
5. How does claim construction influence the outcome of patent litigation?
Claim construction defines the scope of the patent rights; a broad interpretation may favor patent holders, while narrower readings can limit infringement. The court’s interpretation shapes all subsequent judgments.
Sources
- U.S. District Court for the District of New Jersey. (2014). PAR Pharmaceutical, Inc. v. Breckenridge Pharmaceutical, Inc., No. 2:13-cv-04000.
- United States Patent and Trademark Office. (Patent No. 7,849,111).
- United States Patent and Trademark Office. (Patent No. 8,123,456).
- Federal Circuit case law on polymorph patents and obviousness.
